Forward Pharma A/S (FWP) Stock Rating Lowered by ValuEngine

Forward Pharma A/S (NASDAQ:FWP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Separately, BidaskClub upgraded shares of Forward Pharma A/S from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 30th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $24.00.

Forward Pharma A/S (NASDAQ FWP) traded up 35.28% during trading on Tuesday, reaching $6.99. 1,764,707 shares of the company were exchanged. The firm’s market cap is $329.81 million. The firm has a 50-day moving average of $24.86 and a 200-day moving average of $22.69. Forward Pharma A/S has a 52-week low of $5.46 and a 52-week high of $33.00.

WARNING: “Forward Pharma A/S (FWP) Stock Rating Lowered by ValuEngine” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://sportsperspectives.com/2017/09/12/forward-pharma-as-fwp-stock-rating-lowered-by-valuengine.html.

Several institutional investors have recently added to or reduced their stakes in FWP. MARSHALL WACE ASIA Ltd acquired a new position in shares of Forward Pharma A/S in the first quarter valued at approximately $612,000. Marshall Wace North America L.P. acquired a new position in shares of Forward Pharma A/S in the first quarter valued at approximately $612,000. Citadel Advisors LLC acquired a new position in shares of Forward Pharma A/S in the first quarter valued at approximately $269,000. EcoR1 Capital LLC acquired a new position in shares of Forward Pharma A/S in the first quarter valued at approximately $108,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Forward Pharma A/S in the first quarter valued at approximately $2,465,000. Institutional investors own 21.85% of the company’s stock.

About Forward Pharma A/S

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply